ACAD - Acadia Pharmaceuticals Inc.

ACAD

$18.62 0.79 (-4.07%)

After Hours: $18.62 +0.00 (+0.00%)

Last updated: Oct 13, 2026 22:14

52-Week Range

$18.62

$18.39 $18.62 $30.96

Fundamentals Overview

Acadia Pharmaceuticals Inc. is near the low of its 52-week range with attractive valuation, trending downward today.

Valuation attractive

P/E 9 PEG 0.13 P/B 3.32 P/S 2.99

Profitability

ROE 32.39% Net margin 33.4%

Risk (Beta)

0.9 — in line vol

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Buy — 68% confidence Risk: Moderate Volatility — Beta 0.9. Diversify and only invest what you can afford to lose.

Supporting (Buy):

P/E 9 (value) · PEG 0.13 (growth vs price)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

$3.34B

P/E (TTM)

8.96

EPS (TTM)

N/A

Dividend Yield

N/A

52-Week Range

$18.39 - $30.96

Volume vs Avg

100% of avg (Below)

Beta

0.9

About

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psyc...

Sector: Healthcare

Headquarters: US

Website: www.acadia.com

Beta: 0.9 (Less volatile than market)

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

Metric	Value
Valuation
P/E (TTM)	8.96
PEG (TTM)	0.13
P/B (TTM)	3.32
P/S (TTM)	2.99
Profitability
ROE (TTM)	32.39%
ROA (TTM)	24.38%
Revenue growth (YoY)	N/A
Net margin (TTM)	33.42%
Gross margin (TTM)	91.13%
Operating margin (TTM)	7.59%
Debt to equity (TTM)	0

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for ACAD.

Loading analyst coverage...

Price target data is not available for this symbol from the current data source.

Stock Grades (Institutions)

No stock grades available for this symbol.

No price targets, ratings snapshot, or grades available for this symbol.